SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — May 4, 2017

Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: May 4, 2017 · CIK: 0000921114 · Accession: 0001144204-17-024346

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-217169

Date

May 4, 2017

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)

Letter

Re: AmpliPhi Biosciences Corporation

May 4, 2017

VIA EDGAR

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1 (Registration No. 333-217169) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by AmpliPhi Biosciences Corporation that the effective date of the above-referenced registration statement be accelerated to 5:00 P.M. (Eastern Time), or as soon as practicable thereafter, on May 8, 2017, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

May 4, 2017

VIA EDGAR

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 Re: AmpliPhi Biosciences Corporation

Registration Statement on Form S-1 (Registration
No. 333-217169) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”),
as underwriter for the referenced offering, hereby concurs in the request by AmpliPhi Biosciences Corporation that the effective
date of the above-referenced registration statement be accelerated to 5:00 P.M. (Eastern Time), or as soon as practicable thereafter,
on May 8, 2017, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the
Securities Act in connection with this offering.

    Very truly yours,

    H.C. WAINWRIGHT & CO., LLC

    By:
       /s/ Mark W. Viklund

    Name: Mark W. Viklund

    Title: Chief Executive Officer

430 Park Avenue | New York, New York 10022 | 212.356.0500

Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC

SecProbe.io